POLQ is a promising radiosensitizer for prostate cancer – APCCC
Advanced Prostate Cancer Consensus Conference (APCCC) shared on LinkedIn:
“The Proteogenomics of Prostate Cancer Radioresistance out on AACR Journals Cancer Research Communications.
Prostate Cancer radioresistance remains a challenge in radiotherapy, with aggressive relapses often occurring, but the underlying molecular mechanisms are not well understood.
This study analyzed the genomic transcriptomic, and proteomic profiles of prostate cancer cells exposed to both conventional and hypofractionated radiotherapy, revealing that radioresistance is associated with genomic instability and impaired DNA mismatch repair, regardless of the treatment regimen.
Key cancer driver genes exhibited distinct RNA and protein-level changes, with conventional fractionation triggering a more aggressive biomolecular response than hypofractionation.
The study identified POLQ (DNA Polymerase Theta) as a promising radiosensitizer, demonstrating its ability to modulate radioresistance and predict treatment outcomes in patient cohorts, providing new insights into the lethal nature of prostate cancer.”
Source: APCCC/LinkedIn
Authors: Roni Haas, Gavin Frame, Shahbaz Khan, Beth K. Neilsen, Boon Hao Hong, Celestia P.X. Yeo, Takafumi N. Yamaguchi, Enya H.W. Ong, Wenyan Zhao, Benjamin Carlin, Eugenia L.L. Yeo, Kah M. Tan, Yuan Zhe Bugh, Chenghao Zhu, Rupert Hugh-White, Julie Livingstone, Dennis J.J. Poon, Pek L. Chu, Yash Patel, Shu Tao, Vladimir Ignatchenko, Natalie J. Kurganovs, Geoff S. Higgins, Michelle R. Downes, Andrew Loblaw, Danny Vesprini, Amar U. Kishan, Melvin L.K. Chua, Thomas Kislinger, Paul C. Boutros, Stanley K. Liu